Li Taka Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 05-12-2024
- Paid Up Capital ₹ 0.86 M
as on 05-12-2024
- Company Age 43 Year, 6 Months
- Last Filing with ROC 31 Mar 2013
- Open Charges ₹ 1.06 Cr
as on 05-12-2024
About Li Taka Pharmaceuticals
The Corporate was formerly known as Bora Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2013. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 0.86 M.
The company currently has active open charges totaling ₹1.06 Cr.
Pravinkumar Mutha, Suresh Raka, Cajetan Dsouza, and One other member serve as directors at the Company.
- CIN/LLPIN
U24246MH1981PLC024490
- Company No.
024490
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
27 May 1981
- Date of AGM
30 Sep 2013
- Date of Balance Sheet
31 Mar 2013
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Li Taka Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pravinkumar Mutha  | Director | 26-Mar-2009 | Current |
| Suresh Raka | Director | 26-Mar-2009 | Current |
| Cajetan Dsouza | Director | 01-Mar-2008 | Current |
| Omprakash Pattanayak | Director | 01-Oct-2011 | Current |
Financial Performance and Corporate Structure Insights of Li Taka Pharmaceuticals.
Enhance accessibility to Li Taka Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Li Taka Pharmaceuticals?
Unlock access to Li Taka Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Borachem Industries LimitedActive 49 years 3 monthsSuresh Raka and Omprakash Pattanayak are mutual person
- Pegasus Healthcare LimitedActive 20 years 10 months
Suresh Raka and Cajetan Dsouza are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Vishweshwar Sahakari Bank Ltd. Creation Date: 12 Aug 2003 | ₹4.00 M | Open |
Jana Seva Shahakari Bank Ltd. Creation Date: 23 Sep 1999 | ₹0.56 M | Open |
Jana Seva Shahakari Bank Ltd. Creation Date: 27 May 1999 | ₹2.00 M | Open |
How Many Employees Work at Li Taka Pharmaceuticals?
Unlock and access historical data on people associated with Li Taka Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Li Taka Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Li Taka Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
